Review of the latest local treatments for uveitis

Pooja V. Bhat, Debra A. Goldstein*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


There have been many recent advances in local therapeutic options for uveitis, both corticosteroid and non-corticosteroid. Long- and short-acting steroid implants are now available, with new ones being developed. There are also new locations for drug delivery (suprachoroidal space) and new non-corticosteroid options. This paper reviews the data on the currently available local treatment options, as well as those currently under investigation. The choice of local therapy depends on whether or not there is systemic inflammatory disease also requiring treatment, if the disease is unilateral or bilateral, expected disease duration, patient preference and co-existing ocular and systemic comorbidities. For chronic disease without systemic manifestations, long-term steroid releasing implants are a good option, whereas for breakthrough inflammation and cystoid macular edema, short-term intravitreal therapy, initially with corticosteroids then with alternative agents is considered.

Original languageEnglish (US)
Pages (from-to)401-412
Number of pages12
JournalExpert Review of Ophthalmology
Issue number5
StatePublished - Oct 1 2014


  • Triesence
  • intravitreal
  • kenalog
  • methotrexate
  • panuveitis
  • sirolimus
  • steroid
  • suprachoroidal
  • triamcinolone
  • uveitis

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry


Dive into the research topics of 'Review of the latest local treatments for uveitis'. Together they form a unique fingerprint.

Cite this